Oncternal Therapeutics (NASDAQ: ONCT) is one of 672 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Oncternal Therapeutics to similar businesses based on the strength of its risk, profitability, analyst recommendations, institutional ownership, valuation, dividends and earnings.

Analyst Recommendations

This is a summary of recent ratings and price targets for Oncternal Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncternal Therapeutics 0 0 1 0 3.00
Oncternal Therapeutics Competitors 7185 19598 37431 1499 2.51

Oncternal Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 273.83%. As a group, “Pharmaceutical preparations” companies have a potential upside of 38.45%. Given Oncternal Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Oncternal Therapeutics is more favorable than its competitors.

Institutional and Insider Ownership

13.6% of Oncternal Therapeutics shares are owned by institutional investors. Comparatively, 44.6% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 10.9% of Oncternal Therapeutics shares are owned by company insiders. Comparatively, 15.2% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares Oncternal Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oncternal Therapeutics -778.45% -147.33% -92.60%
Oncternal Therapeutics Competitors -3,812.64% -185.53% -31.67%

Volatility and Risk

Oncternal Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Oncternal Therapeutics’ competitors have a beta of 1.51, meaning that their average stock price is 51% more volatile than the S&P 500.

Earnings and Valuation

This table compares Oncternal Therapeutics and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Oncternal Therapeutics $2.42 million -$34.19 million -1.37
Oncternal Therapeutics Competitors $2.00 billion $245.43 million -1.51

Oncternal Therapeutics’ competitors have higher revenue and earnings than Oncternal Therapeutics. Oncternal Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


Oncternal Therapeutics competitors beat Oncternal Therapeutics on 8 of the 13 factors compared.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company's product pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is being evaluated in a Phase I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; and TK-216, a small-molecule compound that is designed to inhibit E26 transformation-specific oncogene-family oncoproteins, which is being evaluated in a Phase I clinical trial alone and in combination with vincristine to treat Ewing sarcoma, a rare pediatric cancer. It is also developing a chimeric antigen receptor-T product candidate that targets ROR1, which is currently in preclinical development for treating hematologic cancers and solid tumors. The company is headquartered in San Diego, California.

Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.